Revive Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Revive Therapeutics's earnings have been declining at an average annual rate of -5.5%, while the Pharmaceuticals industry saw earnings growing at 46% annually.

Anahtar bilgiler

-5.5%

Kazanç büyüme oranı

12.0%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi23.1%
Gelir büyüme oranın/a
Özkaynak getirisi-77.7%
Net Marjn/a
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

We Think Revive Therapeutics (CSE:RVV) Needs To Drive Business Growth Carefully

Mar 02
We Think Revive Therapeutics (CSE:RVV) Needs To Drive Business Growth Carefully

Gelir ve Gider Dağılımı

Revive Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

CNSX:RVV Gelir, gider ve kazançlar (CAD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-621
31 Mar 240-421
31 Dec 230-422
30 Sep 230-523
30 Jun 230-624
31 Mar 230-826
31 Dec 220-12210
30 Sep 220-15312
30 Jun 220-18315
31 Mar 220-24715
31 Dec 210-22813
30 Sep 210-20811
30 Jun 210-20127
31 Mar 210-1494
31 Dec 200-1292
30 Sep 200-1071
30 Jun 200-530
31 Mar 200-320
31 Dec 190-110
30 Sep 190-110
30 Jun 190-110
31 Mar 190-110
31 Dec 180-210
30 Sep 180-210
30 Jun 180-210
31 Mar 180-220
31 Dec 170-210
30 Sep 170-210
30 Jun 170-210
31 Mar 170-211
31 Dec 160-211
30 Sep 160-211
30 Jun 160-312
31 Mar 160-312
31 Dec 150-311
30 Sep 150-311
30 Jun 150-211
31 Mar 150-211
31 Dec 140-210
30 Sep 140-210
30 Jun 140-110
31 Mar 140-110

Kaliteli Kazançlar: RVV is currently unprofitable.

Büyüyen Kar Marjı: RVV is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: RVV is unprofitable, and losses have increased over the past 5 years at a rate of 5.5% per year.

Büyüme Hızlandırma: Unable to compare RVV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: RVV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).


Özkaynak Getirisi

Yüksek ROE: RVV has a negative Return on Equity (-77.69%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin